How does the implementation of revised Schedule M of Drugs and Cosmetics Act impact pharmaceutical units in India
Pharma units have been granted a 12-month extension to comply with the revised Schedule M of the Act.
- Pharmaceutical units in India have been granted a 12-month extension to comply with the revised Schedule M of the Drugs and Cosmetics Act.
- This extension provides additional time for pharmaceutical companies to make necessary changes to their manufacturing processes to meet the new requirements.
- The revision of Schedule M aims to improve the quality of pharmaceutical products, ensuring better safety and efficacy for consumers.
- Compliance with the updated regulations may involve investments in upgrading equipment, training staff, and implementing quality control measures.
- Failure to comply with the revised Schedule M could lead to regulatory penalties, including fines or shutdown of operations.
Answered
4 months ago